GB0116815D0 - Improved chelator conjugates - Google Patents

Improved chelator conjugates

Info

Publication number
GB0116815D0
GB0116815D0 GBGB0116815.2A GB0116815A GB0116815D0 GB 0116815 D0 GB0116815 D0 GB 0116815D0 GB 0116815 A GB0116815 A GB 0116815A GB 0116815 D0 GB0116815 D0 GB 0116815D0
Authority
GB
United Kingdom
Prior art keywords
chelator conjugates
improved
improved chelator
radiometal
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0116815.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
Nycomed Amersham PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Amersham PLC filed Critical Nycomed Amersham PLC
Priority to GBGB0116815.2A priority Critical patent/GB0116815D0/en
Publication of GB0116815D0 publication Critical patent/GB0116815D0/en
Priority to KR1020047000302A priority patent/KR100932827B1/ko
Priority to PL367273A priority patent/PL207834B1/pl
Priority to AU2002313616A priority patent/AU2002313616A1/en
Priority to IL15931002A priority patent/IL159310A0/xx
Priority to CNA028138643A priority patent/CN1622830A/zh
Priority to HU0400974A priority patent/HU230901B1/hu
Priority to ES02753307T priority patent/ES2719088T3/es
Priority to PCT/NO2002/000250 priority patent/WO2003006491A2/en
Priority to CNA200910127855XA priority patent/CN101537190A/zh
Priority to BR0210886A priority patent/BRPI0210886B8/pt
Priority to NZ530156A priority patent/NZ530156A/en
Priority to JP2003512261A priority patent/JP4510444B2/ja
Priority to CNA2008102133680A priority patent/CN101538313A/zh
Priority to CA2452923A priority patent/CA2452923C/en
Priority to EP20110160125 priority patent/EP2347771A1/en
Priority to EP02753307.4A priority patent/EP1404371B1/en
Priority to RU2003137593/04A priority patent/RU2303042C2/ru
Priority to MXPA04000173A priority patent/MXPA04000173A/es
Priority to BR0210965-4A priority patent/BR0210965A/pt
Priority to DK02745600T priority patent/DK1404377T3/da
Priority to AU2002317317A priority patent/AU2002317317B2/en
Priority to AT02745600T priority patent/ATE304866T1/de
Priority to CA002450690A priority patent/CA2450690C/en
Priority to IL15938802A priority patent/IL159388A0/xx
Priority to RU2003137592/04A priority patent/RU2298012C2/ru
Priority to CNB028140087A priority patent/CN100509061C/zh
Priority to JP2003511875A priority patent/JP5015409B2/ja
Priority to MXPA04000210A priority patent/MXPA04000210A/es
Priority to PCT/GB2002/003168 priority patent/WO2003006070A2/en
Priority to HK04107295.3A priority patent/HK1064585B/en
Priority to ES02745600T priority patent/ES2250671T3/es
Priority to US10/483,455 priority patent/US7597875B2/en
Priority to DE60206272T priority patent/DE60206272T2/de
Priority to HU0401265A priority patent/HU228850B1/hu
Priority to EP02745600A priority patent/EP1404377B1/en
Priority to KR1020047000303A priority patent/KR100892009B1/ko
Priority to CN2009102035216A priority patent/CN101607913B/zh
Priority to IL159310A priority patent/IL159310A/en
Priority to NO20035597A priority patent/NO334093B1/no
Priority to US10/753,729 priority patent/US7521419B2/en
Priority to ZA200400143A priority patent/ZA200400143B/xx
Priority to NO20040084A priority patent/NO333066B1/no
Priority to US12/423,953 priority patent/US7994134B2/en
Priority to US12/571,508 priority patent/US8852550B2/en
Priority to US13/204,935 priority patent/US8299030B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
GBGB0116815.2A 2001-07-10 2001-07-10 Improved chelator conjugates Ceased GB0116815D0 (en)

Priority Applications (46)

Application Number Priority Date Filing Date Title
GBGB0116815.2A GB0116815D0 (en) 2001-07-10 2001-07-10 Improved chelator conjugates
MXPA04000173A MXPA04000173A (es) 2001-07-10 2002-07-08 Compuestos basados en peptidos.
PCT/NO2002/000250 WO2003006491A2 (en) 2001-07-10 2002-07-08 Peptide-based compounds for targeting intergin receptors
BR0210886A BRPI0210886B8 (pt) 2001-07-10 2002-07-08 composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
AU2002313616A AU2002313616A1 (en) 2001-07-10 2002-07-08 Peptide-based compounds for targeting intergin receptors
IL15931002A IL159310A0 (en) 2001-07-10 2002-07-08 Peptide-based compounds
CNA028138643A CN1622830A (zh) 2001-07-10 2002-07-08 肽基化合物
HU0400974A HU230901B1 (hu) 2001-07-10 2002-07-08 Peptidalapú vegyületek és ezeket tartalmazó gyógyszerkészítmények
ES02753307T ES2719088T3 (es) 2001-07-10 2002-07-08 Compuestos con base peptídica para localizar receptores de integrina
KR1020047000302A KR100932827B1 (ko) 2001-07-10 2002-07-08 펩티드계 화합물
CNA200910127855XA CN101537190A (zh) 2001-07-10 2002-07-08 肽基化合物
PL367273A PL207834B1 (pl) 2001-07-10 2002-07-08 Związki na bazie peptydów, ich zastosowanie oraz zawierająca je kompozycja farmaceutyczna
NZ530156A NZ530156A (en) 2001-07-10 2002-07-08 Peptide-based compounds for targeting integrin receptors for use as diagnostic imaging agents
JP2003512261A JP4510444B2 (ja) 2001-07-10 2002-07-08 ペプチドベースの化合物
CNA2008102133680A CN101538313A (zh) 2001-07-10 2002-07-08 肽基化合物
CA2452923A CA2452923C (en) 2001-07-10 2002-07-08 Peptide-based compounds for targeting integrin receptors
EP20110160125 EP2347771A1 (en) 2001-07-10 2002-07-08 Peptide-based compounds for targeted imaging
EP02753307.4A EP1404371B1 (en) 2001-07-10 2002-07-08 Peptide-based compounds for targeting intergin receptors
RU2003137593/04A RU2303042C2 (ru) 2001-07-10 2002-07-08 Соединения на основе пептидов для направленной доставки к рецепторам интегринов
CN2009102035216A CN101607913B (zh) 2001-07-10 2002-07-10 改进的螯合剂缀合物
AT02745600T ATE304866T1 (de) 2001-07-10 2002-07-10 Chelatorkonjugate mit verbesserten eigenschaften
US10/483,455 US7597875B2 (en) 2001-07-10 2002-07-10 Chelator conjugates
AU2002317317A AU2002317317B2 (en) 2001-07-10 2002-07-10 Improved chelator conjugates
BR0210965-4A BR0210965A (pt) 2001-07-10 2002-07-10 Conjugado de quelador, complexo de radiometal, radiofármaco, kit para a preparação do mesmo, composto, e, processo para a preparação do mesmo
CA002450690A CA2450690C (en) 2001-07-10 2002-07-10 Improved chelator conjugates
IL15938802A IL159388A0 (en) 2001-07-10 2002-07-10 Improved chelator conjugates
RU2003137592/04A RU2298012C2 (ru) 2001-07-10 2002-07-10 Улучшенные хелатные конъюгаты
CNB028140087A CN100509061C (zh) 2001-07-10 2002-07-10 改进的螯合剂缀合物
JP2003511875A JP5015409B2 (ja) 2001-07-10 2002-07-10 改良キレート剤結合体
MXPA04000210A MXPA04000210A (es) 2001-07-10 2002-07-10 Conjugados quelantes mejorados.
PCT/GB2002/003168 WO2003006070A2 (en) 2001-07-10 2002-07-10 Improved chelator conjugates
HK04107295.3A HK1064585B (en) 2001-07-10 2002-07-10 Improved chelator conjugates
ES02745600T ES2250671T3 (es) 2001-07-10 2002-07-10 Conjugados de queladores mejorados.
DK02745600T DK1404377T3 (da) 2001-07-10 2002-07-10 Forbedrede chelatorkonjugater
DE60206272T DE60206272T2 (de) 2001-07-10 2002-07-10 Chelatorkonjugate mit verbesserten eigenschaften
HU0401265A HU228850B1 (en) 2001-07-10 2002-07-10 Improved chelator conjugates
EP02745600A EP1404377B1 (en) 2001-07-10 2002-07-10 Improved chelator conjugates
KR1020047000303A KR100892009B1 (ko) 2001-07-10 2002-07-10 개질된 킬레이터 콘쥬게이트
IL159310A IL159310A (en) 2001-07-10 2003-12-11 Cyclic peptide compounds containing sulfur and sulfur bonds Pharmaceutical preparations containing @ them @ and uses @ them @ simulation
NO20035597A NO334093B1 (no) 2001-07-10 2003-12-16 Forbedrede chelatdannerkonjugater, radioaktive metallkomplekser, radiofarmasøytika, sett for fremstilling av radiofarmasøytika, samt bifunksjonelle chelatdannere og fremgangsmåter for fremstilling av slike
US10/753,729 US7521419B2 (en) 2001-07-10 2004-01-08 Peptide-based compounds
ZA200400143A ZA200400143B (en) 2001-07-10 2004-01-08 Improved chelator conjugates.
NO20040084A NO333066B1 (no) 2001-07-10 2004-01-09 Peptidbaserte forbindelser, farmasoytisk sammensetning omfattende en slik forbindelse, anvendelse av en slik forbindelse samt fremgangsmate for a danne bilder av et menneske eller en annen dyrekropp.
US12/423,953 US7994134B2 (en) 2001-07-10 2009-04-15 Peptide-based compounds
US12/571,508 US8852550B2 (en) 2001-07-10 2009-10-01 Chelator conjugates
US13/204,935 US8299030B2 (en) 2001-07-10 2011-08-08 Peptide-based compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0116815.2A GB0116815D0 (en) 2001-07-10 2001-07-10 Improved chelator conjugates

Publications (1)

Publication Number Publication Date
GB0116815D0 true GB0116815D0 (en) 2001-08-29

Family

ID=9918227

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0116815.2A Ceased GB0116815D0 (en) 2001-07-10 2001-07-10 Improved chelator conjugates

Country Status (20)

Country Link
US (2) US7597875B2 (https=)
EP (1) EP1404377B1 (https=)
JP (1) JP5015409B2 (https=)
KR (1) KR100892009B1 (https=)
CN (4) CN101538313A (https=)
AT (1) ATE304866T1 (https=)
AU (1) AU2002317317B2 (https=)
BR (1) BR0210965A (https=)
CA (1) CA2450690C (https=)
DE (1) DE60206272T2 (https=)
DK (1) DK1404377T3 (https=)
ES (1) ES2250671T3 (https=)
GB (1) GB0116815D0 (https=)
HU (1) HU228850B1 (https=)
IL (1) IL159388A0 (https=)
MX (1) MXPA04000210A (https=)
NO (1) NO334093B1 (https=)
RU (1) RU2298012C2 (https=)
WO (1) WO2003006070A2 (https=)
ZA (1) ZA200400143B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972122B2 (en) * 2001-01-05 2005-12-06 Duke University Contrast enhancement agent for magnetic resonance imaging
WO2003006491A2 (en) * 2001-07-10 2003-01-23 Amersham Health As Peptide-based compounds for targeting intergin receptors
NO20030115D0 (no) 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
EP1699495A2 (en) 2003-11-06 2006-09-13 Amersham Health AS Conjugates of angiotensin ii and an imaging moiety
GB0416062D0 (en) * 2004-07-19 2004-08-18 Amersham Plc Improved N4 chelator conjugates
JP2007512321A (ja) * 2003-11-24 2007-05-17 ジーイー・ヘルスケア・アクスイェ・セルスカプ 造影剤
JP2007526300A (ja) * 2004-03-04 2007-09-13 ジーイー・ヘルスケア・アクスイェ・セルスカプ 医薬化合物
ES2358745T3 (es) 2004-11-22 2011-05-13 Ge Healthcare As Agentes de contraste para señalar matriz extracelular.
GB0427392D0 (en) * 2004-12-15 2005-01-19 Amersham Plc Stabilised 99mTc compositions
WO2006131803A2 (en) * 2005-06-08 2006-12-14 Ge Healthcare Limited Method for the use of [11c] carbon monoxide in labeling synthesis of 11c-labelled esters and acids by sensitized photo-induced free radical carbonylation
GB0515974D0 (en) * 2005-08-03 2005-09-07 Ge Healthcare Ltd Compounds and imaging methods
WO2007094683A1 (en) 2006-02-15 2007-08-23 Ge Healthcare As Contrast agents
US7943117B2 (en) * 2006-06-08 2011-05-17 Atomic Energy Council—Institute of Nuclear Research Method for testing radiochemical purity of Tc-99m-TRODAT-1
KR20090097868A (ko) * 2006-12-11 2009-09-16 지이 헬스케어 에이에스 방사선 표지된 펩티드 기재 화합물 및 그의 용도
US9701694B2 (en) 2008-12-02 2017-07-11 The University Of Melbourne Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
EP2598175B1 (en) * 2010-07-27 2020-05-20 Serac Healthcare Limited Radiopharmaceutical compositions
GB201103696D0 (en) 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201110767D0 (en) 2011-06-24 2011-08-10 Ge Healthcare Ltd Infection imaging
US20130195756A1 (en) 2012-01-31 2013-08-01 General Electric Company 99mTc IMAGING AGENTS AND METHODS OF USE
JP2016510342A (ja) * 2013-02-15 2016-04-07 トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ 腫瘍画像化のためのキット
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
EP3131585B1 (en) 2014-03-19 2020-07-15 Universität Zürich Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy
WO2019217571A1 (en) * 2018-05-08 2019-11-14 University Of Miami Materials and methods for the delivery of therapeutic nucleic acids to tissues
EP3793619A4 (en) 2018-05-16 2022-01-12 Emory University Styrylbenzothiazole derivatives and uses in imaging
CN111548275A (zh) * 2020-05-27 2020-08-18 龙曦宁（上海）医药科技有限公司 一种2-（氨基甲基）-n1,n1-二甲基丙烷-1,3-二胺三盐酸盐的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1588978A (en) * 1977-07-19 1981-05-07 Ici Ltd Coating processes
DE3930674A1 (de) * 1989-09-11 1991-03-21 Diagnostikforschung Inst Bifunktionelle chelatbildner zur komplexierung von tc- und re-isotopen, verfahren zu ihrer herstellung und darstellung von konjugaten daraus sowie deren verwendung in diagnostik und therapie
US5849261A (en) * 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
US5808091A (en) * 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
CA2168652A1 (en) * 1993-08-04 1995-02-16 Colin Mill Archer Radiometal complexes that localise in hypoxic tissue
WO1995019187A1 (en) * 1994-01-12 1995-07-20 Amersham International Plc Biological targeting agents
CA2156605A1 (en) * 1994-01-12 1995-07-20 Bracco International B.V. Ligands and metal complexes thereof
IL139385A (en) 1998-05-15 2005-09-25 Amersham Plc Labelled glutamine and lysine analogues, metal complexes thereof, and uses thereof for diagnosis
US6783711B2 (en) * 2000-05-23 2004-08-31 Ge Osmonics, Inc. Process for preparing a sulfonamide polymer matrix
WO2002072718A1 (en) * 2001-03-08 2002-09-19 Matsushita Electric Industrial Co., Ltd. Inkjet recording ink, method for producing said ink, and ink cartridge and recording device having said ink

Also Published As

Publication number Publication date
NO334093B1 (no) 2013-12-09
US20100040542A1 (en) 2010-02-18
MXPA04000210A (es) 2004-07-23
WO2003006070A2 (en) 2003-01-23
AU2002317317B2 (en) 2005-11-17
CA2450690A1 (en) 2003-01-23
JP2005500325A (ja) 2005-01-06
BR0210965A (pt) 2004-06-08
IL159388A0 (en) 2004-06-01
CN101537190A (zh) 2009-09-23
ATE304866T1 (de) 2005-10-15
HUP0401265A2 (hu) 2004-09-28
KR100892009B1 (ko) 2009-04-07
CN101538313A (zh) 2009-09-23
KR20040017287A (ko) 2004-02-26
EP1404377A2 (en) 2004-04-07
US7597875B2 (en) 2009-10-06
WO2003006070A3 (en) 2003-08-21
CN100509061C (zh) 2009-07-08
DE60206272T2 (de) 2006-07-13
HU228850B1 (en) 2013-06-28
CN101607913A (zh) 2009-12-23
NO20035597D0 (no) 2003-12-16
NO20035597L (no) 2004-03-03
EP1404377B1 (en) 2005-09-21
HUP0401265A3 (en) 2005-11-28
JP5015409B2 (ja) 2012-08-29
HK1064585A1 (en) 2005-02-04
US8852550B2 (en) 2014-10-07
DK1404377T3 (da) 2006-01-30
RU2003137592A (ru) 2005-05-20
CA2450690C (en) 2009-03-24
CN101607913B (zh) 2012-07-04
US20040258619A1 (en) 2004-12-23
ZA200400143B (en) 2004-12-29
CN1527727A (zh) 2004-09-08
RU2298012C2 (ru) 2007-04-27
DE60206272D1 (de) 2005-10-27
ES2250671T3 (es) 2006-04-16

Similar Documents

Publication Publication Date Title
ZA200400143B (en) Improved chelator conjugates.
YU27403A (sh) Postupak za pripremanje preparata u obliku praha
IL181529A (en) A method for radiofluorination, a compound containing radioactive fluorine and its use in the preparation of a radioactive drug
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
PL369530A1 (en) Chemical compounds
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
SG147286A1 (en) Manufacture of polyglumate-therapeutic agent conjugates
TWI268278B (en) 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses
TW200716605A (en) 2,6-quinolinyl derivatives, processes for preparing them and their uses
TR200003389T2 (tr) 2-(2-klorofenil)-3,4-dihidro-2H-pirol türevleri.
DE60210598D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
GB0105224D0 (en) Improved peptide-chelate conjugates
DE60322562D1 (de) Konjugate von tc komplexen und zielgerichtete einheiten und ihre verwendung in nmr-diagnostik
PL1831239T3 (pl) Sposób wytwarzania gamma-laktonu kwasu 17-hydroksy-6 beta, 7 beta,15 beta, 16 beta-bismetyleno-17 alpha-pregn-4-en-3-ono-21-karboksylowego i związki pośrednie kluczowe dla tego sposobu
PL352104A1 (en) Oral composition containing perlite
DE60213084D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
ID27733A (id) Metoksiminofenilasetamida
MXPA05008108A (es) Exo-(2r)(+))-2-amino-7-azabiciclo[2.2.1]heptan-7-carboxilato de terc-butilo, compuestos intermedios y procedimiento para prepararlos y aislarlos.
WO2004075028A3 (en) Systems and methods for variable rebate and incentive programs
NO20021429D0 (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
ITMI20030827A1 (it) Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
TW200407314A (en) Preparation of 4, 6-dichloro-5-fluoropyrimidine
ES2183543T3 (es) Derivado de tiocolchicosida, su preparacion y su aplicacion en terapeutica.
BG103595A (en) Metoprolol compound and methods for its preparation
TW200519206A (en) Methods for producing novel medaka and novel medaka

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)